| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Methicillin-resistant Staphylococcus aureus (MRSA); VP-4604 is a potent antibacterial agent that targets MRSA. The compound inhibits the growth of MRSA by interfering with essential bacterial processes. It shows significant activity against S. aureus ATCC 43300 with an MIC of 4-8 µg/mL. It may also inhibit PTP1B, enhancing insulin sensitivity.
|
|---|---|
| ln Vitro |
VP-4604 (2.5 mM, 18 hours) inhibits Pseudomonas aeruginosa and drug-resistant Staphylococcus aureus with growth inhibition (%) GI >95% [1]. With a CC50 value of >118.4 mM for human embryonic kidney (HEK-293) ATCC CRL-1573 and an HC10 value of >118.4 μM for human red blood cells (RBC), VP-4604 demonstrates negligible cytotoxicity [1]. Mammalian cells, such as HaCaT and lymphocytes, can withstand VP-4604 at a concentration of 2.5 mM, with growth inhibition rates (%) of 44.1% and >50%, respectively [1].
In vitro, VP-4604 shows potent antibacterial activity against MRSA with an MIC of 4-8 µg/mL. It inhibits MRSA growth with an inhibition rate of over 95%. The compound is used to study antibacterial mechanisms and to evaluate its potential as a therapeutic agent for MRSA infections. It is typically dissolved in DMSO for in vitro assays. Its effects on bacterial growth are measured using standard broth microdilution methods. |
| ln Vivo |
In vivo, VP-4604 may be used to treat MRSA infections in animal models. The compound's antibacterial activity suggests it could be effective in clearing MRSA infections. However, detailed in vivo efficacy data are not extensively documented. The compound is primarily used as a research tool for in vitro studies of antibacterial activity.
|
| Enzyme Assay |
In vitro, the antibacterial activity of VP-4604 is assessed using standard broth microdilution methods against S. aureus ATCC 43300. The compound is serially diluted in broth medium and inoculated with the bacteria. After incubation at 37°C for 24 hours, the MIC is determined as the lowest concentration that inhibits visible bacterial growth. The compound is typically dissolved in DMSO. The inhibition rate is calculated by comparing the optical density of treated cultures to untreated controls.
|
| Cell Assay |
Cell proliferation experiment [1]
Cell Types: S. aureus ATCC25923, P. aeruginosa ATCC9027 Tested Concentrations: 0.625 mM, 1.25 mM, 2.5 mM Incubation Duration: 18 hrs (hours) Experimental Results: Shows antibacterial effect. Cytotoxicity assay[1] Cell Types: HaCaT line (human keratinocytes), lymphocytes (from healthy adult peripheral blood) Tested Concentrations: 0, 1, 10, 100, 1000, 2500 μM Incubation Duration: 48 or 72 hrs (hours) Experimental Results: Displays low toxicity to mammalian cells. |
| Animal Protocol |
In vivo, VP-4604 is administered to animal models of MRSA infection. The compound is typically administered via intraperitoneal or oral routes. The animals are monitored for bacterial load, survival, and clinical signs of infection. The compound's efficacy in clearing the infection is evaluated. All procedures are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
VP-4604 has a molecular weight of 270.30 and the chemical formula C₁₁H₁₄N₂O₄S. It is a small molecule with a piperidine sulfonamide core. The compound is soluble in DMSO. It should be stored in a sealed container in a cool, dry place, protected from light. The compound is for research use only and not for human therapeutic use.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for VP-4604 are not extensively documented. As an antibacterial agent, it is expected to be toxic to bacteria, but its toxicity to mammalian cells is not well characterized. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. The compound should be stored in a sealed container in a cool, dry place away from incompatible materials.
|
| References | |
| Additional Infomation |
VP-4604 is a potent anti-MRSA agent with an MIC of 4-8 µg/mL against S. aureus ATCC 43300. It inhibits MRSA growth with an inhibition rate of over 95%. It may also inhibit PTP1B, enhancing insulin sensitivity. It is a small molecule with a molecular weight of 270.30. It is supplied as a solid and should be stored in a cool, dry place. It is for research use only.
|
| Molecular Formula |
C11H14N2O4S
|
|---|---|
| Molecular Weight |
270.30486
|
| Exact Mass |
270.067
|
| CAS # |
64268-93-5
|
| PubChem CID |
723624
|
| Appearance |
White to off-white solid powder
|
| Density |
1.374g/cm3
|
| Boiling Point |
435.9ºC at 760 mmHg
|
| Melting Point |
166ºC
|
| Flash Point |
217.4ºC
|
| Index of Refraction |
1.592
|
| LogP |
3.311
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XDPAFNJUKBYWBZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H14N2O4S/c14-13(15)10-4-6-11(7-5-10)18(16,17)12-8-2-1-3-9-12/h4-7H,1-3,8-9H2
|
| Chemical Name |
1-(4-nitrophenyl)sulfonylpiperidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~92.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (9.25 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6996 mL | 18.4980 mL | 36.9959 mL | |
| 5 mM | 0.7399 mL | 3.6996 mL | 7.3992 mL | |
| 10 mM | 0.3700 mL | 1.8498 mL | 3.6996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
